Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2010 - 2025)

Lexicon Pharmaceuticals (LXRX) reported Current Deferred Revenue of $4.3 million for Q3 2025, down 75.35% quarter-over-quarter from $17.5 million in Q2 2025.

Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2010 - 2025) Analysis & Trends

Lexicon Pharmaceuticals (LXRX) has 11 years of Current Deferred Revenue data on file, last reported at $4.3 million in Q3 2025.

  • Current Deferred Revenue for Q3 2025 came in at $4.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $4.3 million (changed N/A YoY), and the FY2018 annual result was $2.3 million, down 94.2% from the prior year.
  • Current Deferred Revenue slipped to $4.3 million in Q3 2025 per LXRX's latest filing, from $17.5 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $45.0 million in Q1 2025 and troughed at $4.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Lexicon Pharmaceuticals 804.48 Mn 633.82 Mn 20.99 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 4.30 Mn
Jun 30, 2025 17.46 Mn
Mar 31, 2025 45.00 Mn
Sep 30, 2019 1.12 Mn
Jun 30, 2019 2.24 Mn
Mar 31, 2019 2.43 Mn
Dec 31, 2018 2.34 Mn
Sep 30, 2018 2.12 Mn
Jun 30, 2018 5.12 Mn
Mar 31, 2018 7.44 Mn
Dec 31, 2017 40.35 Mn
Sep 30, 2017 48.74 Mn
Jun 30, 2017 63.20 Mn
Mar 31, 2017 69.17 Mn
Dec 31, 2016 63.37 Mn
Sep 30, 2016 78.87 Mn
Jun 30, 2016 61.53 Mn
Mar 31, 2016 70.76 Mn
Dec 31, 2015 76.50 Mn
Sep 30, 2015 1.74 Mn